$17.55
0.57% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US45781M1018
Symbol
INVA

Innoviva Stock price

$17.55
-1.50 7.87% 1M
+1.35 8.33% 6M
+1.51 9.41% YTD
+1.28 7.87% 1Y
-0.20 1.13% 3Y
+3.30 23.16% 5Y
+2.71 18.26% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.10 0.57%
ISIN
US45781M1018
Symbol
INVA
Sector
Industry

Key metrics

Market capitalization $1.10b
Enterprise Value $1.29b
P/E (TTM) P/E ratio 25.52
EV/FCF (TTM) EV/FCF 7.94
EV/Sales (TTM) EV/Sales 3.52
P/S ratio (TTM) P/S ratio 3.00
P/B ratio (TTM) P/B ratio 1.64
Revenue growth (TTM) Revenue growth 20.48%
Revenue (TTM) Revenue $366.55m
EBIT (operating result TTM) EBIT $161.25m
Free Cash Flow (TTM) Free Cash Flow $162.29m
Cash position $260.63m
EPS (TTM) EPS $0.69
P/E forward 41.29
P/S forward 3.11
EV/Sales forward 3.64
Short interest 33.78%
Show more

Is Innoviva a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Innoviva Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Innoviva forecast:

1x Buy
50%
1x Hold
50%

Analyst Opinions

2 Analysts have issued a Innoviva forecast:

Buy
50%
Hold
50%

Financial data from Innoviva

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
367 367
20% 20%
100%
- Direct Costs 82 82
14% 14%
22%
284 284
23% 23%
78%
- Selling and Administrative Expenses 71 71
25% 25%
19%
- Research and Development Expense 12 12
70% 70%
3%
201 201
50% 50%
55%
- Depreciation and Amortization 40 40
22% 22%
11%
EBIT (Operating Income) EBIT 161 161
60% 60%
44%
Net Profit 65 65
29% 29%
18%

In millions USD.

Don't miss a Thing! We will send you all news about Innoviva directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Innoviva Stock News

Neutral
Business Wire
13 days ago
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., (“IST”) a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced it has entered into an exclusive distribution and license agreement with Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), for the commercialization of Zevtera® (ceftobiprole), an advanced-generation cephalosporin antibiotic, in the United States. "T...
Neutral
GlobeNewsWire
13 days ago
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, December 16, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an exclusive distribution and license agreement with Innoviva Specialty Therapeutics, In...
Neutral
Business Wire
about one month ago
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will p...
More Innoviva News

Company Profile

Innoviva, Inc. is engaged in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

Head office United States
CEO Pavel Raifeld
Employees 112
Founded 1996
Website www.inva.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today